{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-006473","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.275671+00:00","generated_at":"2026-05-20T22:22:32.058274+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction","bullets":["Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.","Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.","Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.","Topline results expected in the second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-006473","json":"https://secwatch.observer/filing/0001999371-25-006473.json","markdown":"https://secwatch.observer/filing/0001999371-25-006473.md","text":"https://secwatch.observer/filing/0001999371-25-006473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/0001999371-25-006473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/tnxp-8k_052125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:22:32.058274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}